

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

185,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Hemolysin of *Vibrio* Species

Tamaki Mizuno, Anusuya Debnath and Shin-ichi Miyoshi

Abstract

Hemolysin is one of the major pathogenic factors among *Vibrio* species, which shows hemolytic activity against erythrocytes. It is associated with different *Vibrio* spp. that manifest either wound infection or intestinal infection as their clinical symptom. *V. vulnificus* and *V. alginolyticus* are well-known causative organisms for wound infection, whereas the gastrointestinal infection is caused by *V. cholerae*, *V. mimicus*, and *V. parahaemolyticus*. There are two major groups of hemolysins in *Vibrio* spp.: the thermostable direct hemolysin (TDH) from *V. parahaemolyticus* and the HlyA (El Tor hemolysin) from *V. cholerae*. These hemolysins have homology in certain degrees; however, the essential amino acids for the activity are variable depending on the species. This chapter summarizes the functions and features of hemolysins from *Vibrio* species, which has been reported so far.

Keywords: thermostable direct hemolysin, El Tor hemolysin, *Vibrio parahaemolyticus*, *vibrio cholerae*, *vibrio mimicus*, *vibrio vulnificus*

1. Introduction

The genus *Vibrio* is comprised of facultative, anaerobic, Gram-negative, curved-rod bacteria that are widely found in natural aquatic environments such as marine, estuarine, and freshwater [1]. More than 100 species have been currently described in this genus, and at least 12 species represented by *V. cholerae*, *V. parahaemolyticus*, and *V. vulnificus* cause a variety of clinical symptoms in human (Table) [1–5]. In addition, species such as *V. metoecus* and *V. navarrensis* are among the newly isolated species from human, and it is strongly suggested that they are human pathogens of *Vibrio* spp. [6, 7]. On the other hand, the major pathogenic *Vibrio* for aquatic vertebrates or invertebrates are *V. anguillarum*, *V. harveyi*, *V. ordalii* etc., responsible for fatal hemorrhagic septicemic disease called vibriosis in marine animals [5, 8–10]. *Vibrio* spp. prefer warm water temperature (15–35°C), so they are likely to flourish more with rising environmental water temperature due to global warming and thus the probability of infections caused by them.

Human diseases caused by pathogenic *Vibrio* spp. can be divided into two major types based on symptoms: intestinal infection and non-intestinal infection [1, 3]. The intestinal infection includes gastroenteritis and cholera, whereas non-intestinal infection includes septicemia and wound infection (**Table 1**). Cholera is caused by ingestion of food and drinking water contaminated with *V. cholerae* O1/O139 that produces cholera toxin (CT) as a major virulence determinant and characterized by severe diarrhea that rapidly leads to dehydration [11, 12]. Till date it remains a major public health disease with estimated 2.9 million cases and 95,000 deaths annually worldwide [13]. There are many clinical cases of gastroenteritis by *V. parahaemolyticus* due to ingestion of raw fish and shellfish [14, 15].

Species	Diseases	Hemolysin family
<i>V. alginolyticus</i>	Wound infection, otitis media	TDH
<i>V. carchariae</i>	Wound infection	
<i>V. cincinnatiensis</i>	Meningitis	
<i>V. cholerae</i>		
O1/O139	Cholera	HlyA
non-O1/non-O139	Gastroenteritis, wound infection	HlyA, TDH
<i>V. damsela</i>	Wound infection	HlyA
<i>V. fluvialis</i>	Gastroenteritis	HlyA
<i>V. furnissii</i>	Gastroenteritis	
<i>V. hollisae</i>	Gastroenteritis, septicemia	TDH
<i>V. metschnikovii</i>	Cholecystitis	
<i>V. mimicus</i>	Gastroenteritis	HlyA, TDH
<i>V. parahaemolyticus</i>	Gastroenteritis, wound infection	TDH
<i>V. vulnificus</i>	Septicemia, wound infection	HlyA

HlyA, El Tor hemolysin group; TDH, thermostable direct hemolysin family.

Table 1.
Pathogenic *Vibrio* species for human and hemolysins produced by them [1, 3].

The other species such as *V. cholerae* non-O1/non-O139, *V. mimicus*, and *V. fluvialis* are known as agents of foodborne illness [3, 16–19]. On the other hand, *V. vulnificus* is the most studied among *Vibrio* spp. as a causative bacterium of wound infections, though the clinical cases by *V. damsela* and *V. alginolyticus* are also reported [3, 20–24]. *V. vulnificus* is an opportunistic pathogen and poses a threat to individuals with compromised immunity because it can also cause septicemia, which leads to high lethal rates [24–26].

These pathogenic *Vibrio* have been reported to produce various virulence factors, including enterotoxin such as CT produced by *V. cholerae* O1/O139 [12, 27], hemolysin, and Type III secretion system (T3SS) in *V. parahaemolyticus* [28, 29] and extracellular protease in *V. vulnificus* [30]. This chapter has mainly summarized how hemolysins play an important role in the pathogenicity of *Vibrio* spp. based on studies till date.

2. Hemolysins

Hemolysin is a toxin that attacks membranes of mammalian erythrocyte and causes cell lysis called hemolysis. It is reported that hemolysins are produced by different species of bacteria like *Escherichia coli*, *Staphylococcus aureus*, and *Vibrio* [31–34]. In most cases, the evidence based either on in vivo experiments or clinical reports that suggests the involvement of hemolysins in the pathogenicity is reported [33, 35]. This toxin plays certainly an important role in the infection process initiated by *Vibrio* spp. Hemolysin from *Vibrio* spp. can be classified mainly into two groups, thermostable direct hemolysin (TDH) from *V. parahaemolyticus* and El Tor hemolysin (HlyA) from *V. cholerae*. Even though these toxins partially share the sequence homology, the essential amino acids for the activity, structural features, and function are different between TDH and HlyA.

2.1 Thermostable direct hemolysin (TDH), TRH, and others

2.1.1 Thermostable direct hemolysin (TDH)

V. parahaemolyticus was first isolated by Fujino et al. as a causative agent of food poisoning in Osaka, Japan [14]. The pathogenicity of *V. parahaemolyticus* is determined by multiple virulence factors including adhesins, thermostable direct hemolysin (Vp-TDH), TDH-related hemolysin (Vp-TRH), and two type III secretion systems (T3SS), T3SS1 and T3SS2 [28]. It has been reported that the clinical isolates of *V. parahaemolyticus* show β -hemolysis activity on Wagatsuma blood agar medium [36], whereas almost all non-clinical isolates are non-hemolytic. This hemolytic activity has been given a specific term known as Kanagawa phenomenon (KP), and it is due to Vp-TDH encoded by the *tdh* gene [37, 38]. Thus, Vp-TDH has been considered as an important virulence factor in gastroenteritis cases and KP reaction as a good marker for the identification of pathogenic strains. Thermostable direct hemolysin, Vp-TDH, was named so because of its characteristics. These characters include persistence of activity even after heating at 100°C for 10 minutes and the ability to act directly on erythrocytes with no enhancement in activity level even by the addition of lecithin [39]. This purified toxin has numerous biological activities such as hemolytic activity for erythrocytes of various species, cytotoxic activity for some mammalian cells, and enterotoxic activity measured by fluid accumulation (FA) in the rabbit ileal loop test [33, 40–42].

The mature form of Vp-TDH consists of 165 amino acids and is approximately of 19 kDa. It exists as a tetramer in solution, which is responsible for the membrane disruption [43, 44]. This is a pore-forming toxin, but it has no similarities with other bacterial pore formers except Vp-TDH homologs like Vp-TRH and TDH-like toxins from *V. cholerae* non-O1/non-O139, *V. mimicus*, and *V. hollisae* [45–49]. Vp-TDH forms pores of approximately 2 nm in diameter on erythrocyte membrane that results into colloidal osmotic lysis [50]; however, the exact mechanism of pore formation is not yet identified. The reactivity of Vp-TDH against erythrocytes from various animal species showed variability; for example, it causes hemolysis of erythrocytes from rat, human, rabbit, and sheep but not horse [51]. It is reported that the amino acid residues, Arg⁴⁶, Gly⁶², Trp⁶⁵, and Gly⁹⁰, are critical for the hemolysis; in fact, the substitution of residue Arg⁴⁶ by site-directed mutagenesis inhibits the formation of tetramer [33, 44, 52].

Enterotoxicity, which is another feature of Vp-TDH, has been evaluated by increase of FA in the rabbit ileal loop due to intestinal Cl[−] secretion as a manifestation of diarrhea induced by *V. parahaemolyticus*. The Cl[−] secretion from human colonic epithelial cells by Vp-TDH is caused by stimulation of Ca²⁺-activated chloride ion channel not by pore formation on the cells [53]. Evidence suggests that Vp-TDH acts in three sequential steps: receptor binding on the epithelial cells, followed by increase in intracellular Ca²⁺ concentration due to protein kinase C activation, and finally, stimulation of Ca²⁺-activated Cl[−] channel. However, it is reported that the deletion of *tdh* only leads to partial decrease in enterotoxicity against rabbit intestinal cells, whereas cytotoxicity to Hela cells was not affected at all [54]. Moreover, a recent study provides a new evidence that Vp-TDH can also engage as an effector of T3SS and implicated to elevate FA in animal model [55]. Therefore, the reason behind pathogenicity of *V. parahaemolyticus* is perhaps not only because of Vp-TDH but also because it involves a synergistic action of multiple virulence factors including T3SS.

2.1.2 TDH-related hemolysin (Vp-TRH) and others

Vp-TRH is identified as a new hemolysin found in KP-negative strains from clinical samples, named TDH-related hemolysin (Vp-TRH) [45]. Vp-TRH protein has a conserved domain of Vp-TDH and immunologically similar to Vp-TDH. But unlike Vp-TDH, it is heat-labile and lost its activity when heated at 60°C for 10 minutes. It is reported that there are significant nucleotide differences that exist within the *trh* family of two subgroups (*trh1* and *trh2*), sharing 84% sequence identity, as opposed to the less diversity (<3.3%) of five *tdh* genes (*tdh1* to *tdh5*) [38, 56–58]. Vp-TRH also induces chloride ion secretion in human colonic epithelial cells like Vp-TDH; therefore, it is considered as one of the important virulence factors among KP-negative strains of *V. parahaemolyticus* [59].

TDH-like toxins have also been found in *V. cholerae* non-O1/non-O139, *V. mimicus*, and *V. hollisae* known as NAG-TDH, Vm-TDH, and Vh-TDH, respectively [47–49]. It is reported that all clinical isolates of *V. hollisae* possess *tdh* gene [60], whereas only some clinical strains of *V. cholerae* non-O1/non-O139 and *V. mimicus* contain *tdh* gene [46, 61]. The molecular weight of these toxins is similar to Vp-TDH and shows immunological cross-reactivity with Vp-TDH. Both NAG-TDH and Vm-TDH are stable on heating at 100°C for 10 minutes, and the hemolytic activity against erythrocytes of most animals is almost similar to Vp-TDH [47, 48]. On the other hand, Vh-TDH is a heat-labile toxin that gets inactivated by heating at 70°C for 10 minutes, unlike Vp-TDH [49]. Moreover, it is reported that *V. alginolyticus* also produce TDH-like toxin, and it shows toxicity for mouse and fish [62].

2.2 HlyA (El Tor hemolysin) and related toxins

2.2.1 HlyA of *V. cholerae*

V. cholerae O1/O139 is the causative agent of cholera, and its main virulence factors are cholera toxin (CT) and toxin-coregulated pilus (TcpA) [11, 12]. *V. cholerae* produces some other virulence factors such as hemolysin, hemagglutinin/protease (HA/protease), T3SS, etc., which can also serve as important elements for the pathogenesis, especially in the strains devoid of CT and TcpA [63–65]. The water-soluble cytolytic toxin produced by *V. cholerae* El Tor O1 and non-O1/non-O139 strains is known as El Tor hemolysin (HlyA)/*V. cholerae* cytolysin (VCC) [66, 67]. HlyA can facilitate lysis of erythrocytes from various animals and other mammalian cells [66, 68]. It can also exhibit potent enterotoxicity as measured by fluid accumulation in the rabbit ileal loop test. Thus, HlyA has been considered to play a crucial role in the pathogenesis of gastroenteritis caused by *V. cholerae* strains [63].

The HlyA encoded by *hlyA* gene is produced in the form of 82 kDa inactive precursor, termed pre-pro-HlyA [69, 70]. This 82 kDa precursor consists of 25 amino acid long signal peptide at the N-terminal, a pro-region of 14 kDa and mature region of 65 kDa at the C-terminal. The mature form of HlyA is generated via a two-step process [71]. In the first step, the 82 kDa precursor is converted to 79 kDa pro-HlyA by cleavage of the signal peptide during its translocation through the inner membrane and then secreted extracellularly in an inactive form. In the second step, the inactive pro-HlyA is converted to active HlyA through the proteolytic removal of pro-region, usually at the bond between Ala¹⁵⁷ and Asn¹⁵⁸ (**Figure 1**; Proteolytic cleavage site). It has been found that the pro-HlyA can be activated by extracellular metalloprotease (HA/protease), a major protease of *V. cholerae* and also by other exogenous or endogenous proteases. However, the exact proteolytic cleavage site depends on the specificity of the protease, which is different compared to native processing [72]. Moreover, it is reported that pro-HlyA can




Figure 1. Comparison between *V. cholerae* hemolysin (HlyA) and other *Vibrio* spp. hemolysins. HlyA of *V. cholerae* consists of pro-region (light blue), cytolysin domain (blue), β -trefoil lectin domain (pink), and β -prism lectin domain (yellow). There is a proteolytic cleavage site (gray) between pro-region and cytolysin domain for the conversion of pro-HlyA to mature HlyA. The hemolysins from *V. mimicus* and *V. fluvialis* have no significant differences in domain construction. *V. vulnificus* hemolysin lacks β -prism lectin domain and pro-region; instead, *V. vulnificus* produces VvhB that might act as chaperon-like pro-region. *V. damsela* produces HlyA-like hemolysin without β -prism lectin domain.

bind as a monomer to eukaryotic cell membrane, and then this bound pro-HlyA can be activated by exogenous, endogenous, extracellular, and even by cell-bound proteases [73]. It is well known that the pro-region can act as an intramolecular chaperone, an essential role of pro-region that governs the proper folding of HlyA pro-toxin [74].

HlyA belongs to bacterial β -barrel pore-forming toxins (β -PFTs) family that includes α -hemolysin of *Staphylococcus aureus* and aerolysin of *Aeromonas hydrophila* [75–77]. Consistent with generalized mode of action by β -PFT, the pore formation mechanism of HlyA has been proposed to follow three distinct steps (**Figure 2**); binding as a water-soluble monomer onto the target cell membrane, formation of pre-pore oligomeric intermediates by the self-assembly of toxin monomer, and finally insertion of the pore-forming stem-loop into the membrane, resulting into the formation transmembrane heptameric β -barrel pores on the cell membrane [78–80]. HlyA causes colloid osmotic lysis of mammalian cells by forming transmembrane pores on the target cell membranes [81, 82], which causes not only hemolysis but also potent cytotoxic effect such as vacuolation [83] and apoptosis [84, 85] of epithelial and immune cells.

The PFTs show affinity for a wide range of cell surface molecules such as cholesterol [86], glycosylphosphatidylinositol-anchored glycoproteins [87], and the human complement receptor CD59 [88]. In case of human erythrocyte membrane, glycophorin B has been reported to be a receptor for HlyA [89]. The hemolysis of rabbit erythrocytes by HlyA is competitively inhibited by asialofetuin and glycoproteins with multiple β_1 -galactosyl residues [90]; this provides an evidence that cell surface carbohydrates are acting as functional receptors. *V. cholerae* cytolysin also shows strong preference for cholesterol- and sphingolipid-rich vesicles [91]. So, it can be said like other PFTs, HlyA also shows affinity for multiple cell surface receptor.

The mature HlyA is composed of three distinct domains: a central cytolysin domain and two lectin-like domains with β -trefoil and β -prism folds. The β -trefoil and β -prism domains exhibit structural homology to the carbohydrate-binding




Figure 2.

Mechanism of transmembrane heptameric pore formation by HlyA. (a) Pro-HlyA structure. (b) Secreted pro-HlyA is activated through the removal of pro-region by protease. (c) HlyA monomer binds to the target membrane by using a rim region and/or β-prism lectin domain with membrane component such as cholesterol and carbohydrate receptor, respectively. (d) HlyA monomer assembles to heptameric pre-pore oligomeric intermediates. (e) The pre-stem of HlyA is inserted into the membrane, resulting into the formation of transmembrane heptameric β-barrel pores.

domain of the plant lectin ricin and jacalin, respectively [78]. In fact, the 15 kDa β-prism lectin domain has carbohydrate-binding activity [92], and the deletion of 15 kDa β-prism lectin domain generates a 50 kDa variant (HlyA50) with no effect on the global conformation of the monomer, but the hemolytic activity reduced by approximately 1000-fold [93, 94]. The β-prism domain has been shown to promote self-assembly of the toxin monomer in carbohydrate-independent manner, suggesting the hemolytic activity of HlyA50 is compromised due to reduction in pre-pore oligomeric intermediates [95]. Another study proposed the role of β-trefoil domain and showed that it is critical for the folding of cytolysin domain to its active conformation [96]. Recently, it is reported that the three loop sequences located in the bottom tip of the cytolysin domain play a critical role in the initial interaction with membrane lipid bilayer. This study showed that the replacement of the amino acid residues in the three loop sequences designated as “rim region” compromises the specific interaction of HlyA monomer with membrane lipid bilayer and blocks the pore formation process. Thus, it leads to repression in the lysis of human erythrocytes and reduced cytotoxic activity for HT-29 human colorectal adenocarcinoma cells [97]. In the next step that is pre-pore oligomerization, it has been shown that alteration of key amino acids affects not only the formation of oligomeric intermediates but also the subsequent formation of functional transmembrane pore [98]. Finally, pre-pore oligomeric intermediates lead to the formation of transmembrane β-barrel pore. Paul et al. confirmed that the transmembrane stem region plays a significant role in the functional pore formation. However, the deletion of “pre-stem” loop of cytolysin domain does not affect the membrane binding and pre-pore heptamer formation [99]. Therefore, it is considered that each step of HlyA pore formation mechanism plays an indispensable role in the generation of functional transmembrane pore in the target cell and thus enhances the virulence of *V. cholerae*.

2.2.2 Other related El Tor hemolysin of *Vibrio* species

Several studies have reported that other *Vibrio* species such as *V. mimicus*, *V. vulnificus*, and *V. fluvialis* also produce hemolysin that shares some common structural features with HlyA [100–102].

V. mimicus, a species closely related to *V. cholerae*, is a causative agent of human gastroenteritis [103]. Pathogenic strains of *V. mimicus* exhibit various clinical symptoms from watery to dysentery-like diarrhea [104]. This pathogen produces many kinds of virulence factors such as CT-like enterotoxin and heat-stable enterotoxin [105–108], with Vm-TDH as a causative factor in some clinical strains. However, most clinical strains lack the ability to produce any of these toxins. The heat-labile hemolysin/cytolysin (*V. mimicus* hemolysin; VMH) is thought to be the most common virulent enteropathogenic factor [109, 110]. In fact, VMH induces FA in a ligated rabbit ileal loop in dose-dependent manner, and the antibody against VMH apparently reduces enterotoxicity by *V. mimicus* in the living cells [100, 111]. These findings indicate that VMH is potentially related to pathogenesis of this pathogen. The enterotoxic activity of VMH might be due to intestinal Cl^- secretion caused by the activation of both Ca^{2+} -dependent and cyclic AMP-dependent Cl^- secretion systems [111, 112]. Similar to HlyA, it has been indicated that VMH is also a pore-forming toxin. This toxin can disrupt various mammalian erythrocytes including bovine, rabbit, sheep, human, and mouse in colloid osmotic manner, and it shows the highest sensitivity for the horse erythrocytes [100].

VMH encoded by *vmhA* gene is predicted to be of 83 kDa with 82% similarity with *V. cholerae* HlyA. VMH is also secreted as 80 kDa precursor known as pro-VMH [113], which is then converted to 66 kDa mature toxin through the removal of N-terminal propeptide by trypsin-like protease of *V. mimicus* between the amino acid residues Arg^{151} and Ser^{152} [114, 115]. It has been assumed that VMH might be processed in a two-step reaction just like HlyA and pro-toxin can be activated by various proteases such as trypsin, chymotrypsin, and metalloprotease [115, 116]. Similar to 50 kDa variant of HlyA, mature VMH can be converted to 51 kDa of VMH (designated VMH51) through the removal of 15 kDa from C-terminal end by metalloprotease of *V. mimicus*. VMH51 almost showed no lytic activity toward horse erythrocytes because it lost the binding affinity toward erythrocyte membrane [116]. However, the VMH51 can associate with sheep erythrocyte membranes though the affinity is reduced as compared with intact VMH, suggesting that the truncated toxin interacts with other components in sheep erythrocyte membrane. It might be concluded that the 15 kDa C-terminal domain of VMH is functionally similar to β -prism lectin domain of HlyA.

V. fluvialis is one of the foodborne pathogens which can cause clinical symptoms similar to *V. cholerae* [117–119]. *V. fluvialis* secretes El Tor-like hemolysin, designed as *V. fluvialis* hemolysin (VFH), which can elicit lysis of erythrocytes from various animal. In addition to hemolytic activity, VFH can also trigger cytotoxicity toward Chinese hamster ovary (CHO) cells and induction of fluid accumulation in suckling mouse [102]. The purified VFH has molecular weight of 63 kDa, whose N-terminal amino acid sequence shares homology to HlyA from *V. cholerae* and VMH from *V. mimicus* [102]. It is suspected that VFH might play an important role in *V. fluvialis* pathogenicity.

V. vulnificus was first isolated from a leg ulcer, and it was wrongly reported as *V. parahaemolyticus* [120]. Later, it was found that some characters were different from *V. parahaemolyticus* such as positive lactose fermentation, so subsequently it was termed as *V. vulnificus* [20]. *V. vulnificus* can cause two types of illness, the primary septicemia and the wound infection [24]. The former is remarkable for its high fatality rate (over 50%). The primary septicemia is caused by the consumption

of raw seafood, especially shellfish such as oyster contaminated by *V. vulnificus*, and it is reported that 95% of all seafood-related deaths are caused by *V. vulnificus* in the United States [121, 122]. Because most septicemia patients have an underlying disease such as hepatic cirrhosis, hepatitis, or diabetes, the septicemia by *V. vulnificus* is considered as an opportunistic infection [24]. Wound infections characterized clinical symptoms are edema, erythema, or necrosis and occurred after exposure to contaminated seawater or marine products. However, gastrointestinal symptom like diarrhea is very rare due to *V. vulnificus* infection [25, 26]. *V. vulnificus* produces various extracellular virulence factors such as hemolysin or protease [123, 124]. Hemolysin secreted by *V. vulnificus* called as *V. vulnificus* hemolysin (VVH) is also a toxin that can form pore on the target membranes of various mammalian cells. Purified VVH exhibits lytic activity against erythrocytes of various mammals and cultured cells such as CHO, mast, and pulmonary endothelial cells [101, 125–127]. In addition, it is reported that the sublytic doses of hemolysin can trigger apoptotic signaling pathway in human vascular endothelial cell line, ECV304 cells [128], and oligomerization of VVH is essential for the apoptotic activity in CHO cells [129].

VVH (VvhA) precursor has molecular weight of 51 kDa encoded by the structure gene *vvhA*, which constitutes an operon with *vvhB* gene. The *vvhB* gene is present upstream of *vvhA* and encodes 18 kDa protein VvhB. The VvhA precursor is composed of a signal peptide (20 amino acid residues) and cytolysin domain (Gln¹ to Arg³¹⁸) including a putative pre-stem and β -trefoil lectin-like domain (His³¹⁹ to Leu⁴⁵¹) (**Figure 1**); the pro-region and β -prism lectin domain are absent as compared with HlyA precursor [78, 130]. Although the function of VvhB is unknown, it might act as a chaperon in the absence of the pro-region like HlyA. This speculation is supported by the fact that even though VvhA is expressed in the absence of *vvhB* in vitro, the hemolytic activity cannot be detected [131]. Although VVH lacks β -prism lectin domain, the β -trefoil lectin domain has displayed binding capability for glycerol, N-acetyl-D-galactosamine, and N-acetyl-D-lactosamine unlike HlyA [92, 130]. In fact, VVH exhibits decreased ability to bind CHO cells when preincubated with methyl-beta-cyclodextrin, an oligosaccharide, and, thus, inhibition of its cytotoxic effect [132]. Similar to HlyA, it is believed that the VVH monomer binds to the cell membrane and forms oligomers [101, 133, 134] and the crystal structure of β -trefoil lectin domain of VVH reveals a heptameric ring arrangement [130]. It is strongly suggested that cholesterol is the receptor for VVH and facilitates conversion of monomer to oligomer [133, 135]. In addition, it is reported that Thr⁴³⁸ in the β -trefoil lectin domain is responsible for binding to cholesterol [131]. On the other hand, Phe³³⁴ in cytolysin domain that is located near the joint of two domains is essential for oligomerization of toxin monomer [136]. Moreover, it is shown that the mutation of Leu⁴⁵¹ causes inhibition of hemolytic activity without reducing the membrane binding ability; this suggests that the Leu⁴⁵¹ is essential for the oligomer formation [137]. Recently, a study showed that properties such as polarity and indole ring of amino acid Trp²⁴⁶ are essential for the binding of toxin to the target membrane [138]. It is assumed that hemolytic process of VVH is almost similar to HlyA though there are some differences in the function and structure of VVH.

It has been reported that a heat-labile hemolysin purified from *V. tubiashii*, a pathogen of juvenile bivalve, is similar to VVH [139]. Like VVH, this toxin has showed competitive inhibition by cholesterol and can lyse erythrocytes. In addition, the toxin exhibits cytotoxicity to CHO, Caco-2, and Atlantic menhaden liver cells in tissue culture.

V. damsela has been reported to cause wound infection by handling of fish, exposure to seawater and marine animals, and ingestion of raw seafood [21, 140–143]. It has been considered that there is not any other hemolysin in this bacterium, except of a hemolysin with phospholipase D activity known as damselysin [144].

Recently, it is reported that this bacterium possesses HlyA-like hemolysin encoded within a new virulence plasmid pPHDD1. The characteristics of this new HlyA-like hemolysin from *V. damsela* are not yet identified, but the predicted amino acid sequences show 69% similarity with HlyA of *V. cholerae*, missing the β -prism lectin-like domain (**Figure 1**) [145].

3. Conclusion

This chapter is focused on the hemolysins produced by *Vibrio* species, especially the human pathogens. Hemolysins are classified into two groups, namely, thermostable direct hemolysin (TDH) and El Tor hemolysin (HlyA). This chapter pays attention to Vp-TDH (*V. parahaemolyticus*), HlyA (*V. cholerae*), VMH (*V. mimicus*), and VVH (*V. vulnificus*) because these are well studied in terms of the toxin structure and their relation with the pathogenesis. The mechanism of action by HlyA and the essential amino acid residues have been clarified through the crystal structure of HlyA pro-toxin and the transmembrane heptameric oligomer over the past decade. Although the crystal structure has revealed the structural information about Vp-TDH and VVH, the exact mechanism of pore formation in the target membrane is yet to be studied. Several studies have indicated the involvement of novel virulence factors in pathogenesis like T3SS, but still Vp-TDH and Vp-TRH are considered to be the major virulence factors of *V. parahaemolyticus*, one of the important food poisoning bacteria in Japan and other eastern and Southeast Asian countries. HlyA is thought to be a major factor in CT-negative strains (e.g., *V. cholerae* non-O1/non-O139) that can cause diarrhea because it can induce enterotoxicity as well as apoptosis. *V. mimicus* hemolysin, VMH, is just one of the many enterotoxic factors. Even though there is detailed information about structural composition and mode of action of some of the hemolysin such as Vp-TDH and HlyA, still there is a lack of information about other hemolysins. Therefore, it is necessary to further enhance our knowledge regarding these toxins in order to thoroughly understand the mechanism of pathogenesis for the prevention of endemic infectious diseases associated with these pathogens.

Acknowledgements

This investigation was supported by a grant from the Program of the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID), JP19fm0108002, from Ministry of Education, Culture, Sport, Science and Technology in Japan (MEXT), and from the Japan Agency for Medical Research and Development (AMED).

IntechOpen

IntechOpen

Author details

Tamaki Mizuno*, Anusuya Debnath and Shin-ichi Miyoshi
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,
Okayama University, Okayama, Japan

*Address all correspondence to: mizuno-t@cc.okayama-u.ac.jp

IntechOpen

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

References

- [1] Farmer JJ III, Hickman-Brenner FW. The genera *Vibrio* and *Photobacterium*. In: Balows A, Trüper HG, Dworkin M, Harder W, Schleifer KH, editors. The Prokaryotes. A Handbook on the Biology of Bacteria: Ecophysiology, Isolation, Identification, and Applications. 2nd ed. Berlin (Germany): Springer; 2006. pp. 2952-3011. DOI: 10.1007/0-387-30746-x_18
- [2] LPSN-List of prokaryotic names with standing in nomenclature (bacterio.net). 2015. Available from: <http://www.bacterio.net/index.html>
- [3] Janda JM, Powers C, Bryant RG, Abbott SL. Current perspectives on the epidemiology and pathogenesis of clinically significant *Vibrio* spp. Clinical Microbiology Reviews. 1988;1(3): 245-267. DOI: 10.1128/cmr.1.3.245
- [4] Romalde JL, Dieguez AL, Lasa A, Balboa S. New *Vibrio* species associated to molluscan microbiota: A review. Frontiers in Microbiology. 2013;4:413. DOI: 10.3389/fmicb.2013.00413
- [5] Baker-Austin C, Oliver JD, Alam M, Ali A, Waldor MK, Qadri F, et al. *Vibrio* spp. infections. Nature Reviews. Disease Primers. 2018;4:8. DOI: 10.1038/s41572-018-0005-8
- [6] Kirchberger PC, Turnsek M, Hunt DE, Haley BJ, Colwell RR, Polz MF, et al. *Vibrio metoecus* sp. nov., a close relative of *Vibrio cholerae* isolated from coastal brackish ponds and clinical specimens. International Journal of Systematic and Evolutionary Microbiology. 2014;64:3208-3214. DOI: 10.1099/ijs.0.060145-0
- [7] Gladney LM, Tarr CL. Molecular and phenotypic characterization of *Vibrio navarrensis* isolates associated with human illness. Journal of Clinical Microbiology. 2014;52:4070-4074. DOI: 10.1128/JCM.01544-14
- [8] Frans I, Michiels CW, Bossier P, Willems KA, Lievens B, Rediers H. *Vibrio anguillarum* as a fish pathogen: Virulence factors, diagnosis and prevention. Journal of Fish Diseases. 2011;34:643-661. DOI: 10.1111/j.1365-2761.2011.01379.x
- [9] Austin B, Zhang XH. *Vibrio harveyi*: A significant pathogen of marine vertebrates and invertebrates. Letters in Applied Microbiology. 2006;43:119-124. DOI: 10.1111/j.1472-765X.2006.01989.x
- [10] Schiewe MH, Trust TJ, Crosa JH. *Vibrio ordalii* sp. nov.: A causative agent of vibriosis in fish. Current Microbiology. 1981;6:343-348. DOI: 10.1007/BF01567009
- [11] Howard-Jones N. Robert Koch and the cholera vibrio: A centenary. British Medical Journal. 1984;288:379-381
- [12] Kaper JB, Morris JG, Levine MM. Cholera. Clinical Microbiology Reviews. 1995;8(1):48-86
- [13] Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. PLoS Neglected Tropical Diseases. 2015;9:e0003832. DOI: 10.1371/journal.pntd.000383
- [14] Fujino T, Okuno Y, Nakada D, Aoyama A, Fukai K, Mukai T, et al. On the bacteriological examination of shirasu-food poisoning. Medical Journal of Osaka University. 1953;4:299-304
- [15] Joseph SW, colwell RR, Kaper JB. *Vibrio parahaemolyticus* and related halophilic vibrios. Critical Reviews in Microbiology. 1982;10:77-124. DOI: 10.3109/10408418209113506
- [16] Morris JG, Wilson R, Davis BR, Wachsmuth IK, Riddle CF, Wathen HG, et al. Non-O group 1 *Vibrio cholerae* gastroenteritis in the United States.

- Annals of Internal Medicine. 1981;**94**:656-658. DOI: 10.7326/0003-4819-94-5-656
- [17] Shandera WX, Jhonston JM, Davis BR, Blake PA. Disease from infection with *Vibrio mimicus*, a newly recognized *Vibrio* species. Annals of Internal Medicine. 1983;**99**:169-171. DOI: 10.7326/0003-4819-99-2-169
- [18] Huq MI, Alam AKMJ, Brenner DJ, Morris GK. Isolation of *Vibrio*-like group, EF-6 from patients with diarrhea. Journal of Clinical Microbiology. 1980;**11**:621-624
- [19] Lee JV, Shread P, Furniss AL, Bryant TN. Taxonomy and description of *Vibrio fluvialis* sp. nov. (synonym group F *Vibrios*, group EF6). The Journal of Applied Bacteriology. 1981;**50**:73-94. DOI: 10.1111/j.1365-2672.1981.tb00873.x
- [20] Farmer JJ. *Vibrio* (“*Benecke*”) *vulnificus*: The bacterium associated with sepsis, septicemia, and the sea. Lancet. 1979;**2**:903. DOI: 10.1016/s0140-6736(79)92715-6
- [21] Morris JG Jr, Miller HG, Wilson R, Tacket CO, Hollis DG, Hickman FW, et al. Illness caused by *Vibrio damsela* and *Vibrio hollisae*. Lancet. 1982;**319**:1294-1297. DOI: 10.1016/s0140-6736(82)92853-7
- [22] Pien F, Lee K, Higa H. *Vibrio alginolyticus* infections in Hawaii. Journal of Clinical Microbiology. 1977;**5**:670-672
- [23] Rubin SJ, Tilton RC. Isolation of *Vibrio alginolyticus* from wound infections. Journal of Clinical Microbiology. 1975;**2**:556-558
- [24] Blake PA, Weaver RE, Hollis DG. Disease of humans other than cholera caused by vibrios. Annual Review of Microbiology. 1980;**34**:341-367. DOI: 10.1146/annurev.mi.34.100180.002013
- [25] Linkous DA, Oliver JD. Pathogenesis of *Vibrio vulnificus*. FEMS Microbiology Letters. 1999;**174**:207-214. DOI: 10.1111/j.1574-6968.1999.tb13570.x
- [26] Strom MS, Paranjpye RN. Epidemiology and pathogenesis of *Vibrio vulnificus*. Microbes and Infection. 2000;**2**:177-188. DOI: 10.1016/S1286-4579(00)00270-7
- [27] Mekalanos JJ. Cholera toxin: Genetic analysis, regulation, and role in pathogenesis. Current Topics in Microbiology and Immunology. 1985;**118**:97-118
- [28] Makino K, Oshima K, Kurokawa K, Yokoyama K, Uda T, Tagomori K, et al. Genome sequence of *Vibrio parahaemolyticus*: A pathogenic mechanism distinct from that of *V. cholerae*. Lancet. 2003;**361**:743-749
- [29] Park KS, Ono T, Rokuda M, Jang MH, Okada K, Iida T, et al. Functional characterization of two type III secretion systems of *Vibrio parahaemolyticus*. Infection and Immunity. 2004;**72**:6659-6665. DOI: 10.1128/IAI.72.11.6659-6665.2004
- [30] Miyoshi S, Narukawa H, Tomochika K, Shinoda S. Actions of *Vibrio vulnificus* metalloprotease on human plasma proteinase-proteinase inhibitor systems: A comparative study of native protease with its derivative modified by polyethylene glycol. Microbiology and Immunology. 1995;**39**:959-966. DOI: 10.1111/j.1348-0421.1995.tb03299.x
- [31] Ostolaza H, Bartolomé B, Serra JL, de la Cruz F, Goñi FM. Alpha-haemolysin from *E. coli*. Purification and self-aggregation properties. FEBS Letters. 1991;**280**:195-198. DOI: 10.1016/0014-5793(91)80291-A
- [32] Bhakdi S, Tranum-Jensen J. Alpha-toxin of *Staphylococcus aureus*. Microbiological Reviews. 1991;**55**:733-751

- [33] Iida T, Honda T. Hemolysins produced by *Vibrios*. *Journal of Toxicology - Toxin Reviews*. 1997;**16**:215-227. DOI: 10.3109/15569549709016457
- [34] Zhang XH, Austin B. Haemolysins in *Vibrio* species. *Journal of Applied Microbiology*. 2005;**98**:1011-1019. DOI: 10.1111/j.1365-2672.2005.02583.x
- [35] Shinoda S. Protein toxins produced by pathogenic vibrios. *Journal of Natural Toxins*. 1999;**8**:259-269
- [36] Wagatsuma S. On a medium for hemolytic reaction (in Japanese). *Media Circle*. 1968;**13**:159-162
- [37] Kaper JB, Campen KR, Seidler RJ, Baldini MH, Falkow S. Cloning of the thermostable direct or Kanagawa phenomenon associated haemolysin of *Vibrio parahaemolyticus*. *Infection and Immunity*. 1984;**45**:290-292
- [38] Nishibuchi M, Kaper JB. Nucleotide sequence of the thermostable direct hemolysin gene of *Vibrio parahaemolyticus*. *Journal of Bacteriology*. 1985;**162**:558-564
- [39] Sakurai J, Matsuzaki A, Miwatani T. Purification and characterization of thermostable direct hemolysin of *Vibrio parahaemolyticus*. *Infection and Immunity*. 1973;**8**:775-780
- [40] Ljungh A, Wadström T. Toxins of *Vibrio parahaemolyticus* and *Aeromonas hydrophila*. *Journal of Toxicology - Toxin Reviews*. 1982;**1**:257-307. DOI: 10.3109/15569548209019477
- [41] Takeda Y. Thermostable direct hemolysin of *Vibrio parahaemolyticus*. *Pharmacology and Therapeutics*. 1983;**19**:123-146
- [42] Honda T, Iida T. The pathogenicity of *Vibrio parahaemolyticus* and the role of the thermostable direct hemolysin and related haemolysins. *Reviews in Medical Microbiology*. 1993;**4**:106-113
- [43] Hamada D, Higurashi T, Mayanagi K, Miyata T, Fukui T, Iida T, et al. Tetrameric structure of thermostable direct hemolysin from *Vibrio parahaemolyticus* revealed by ultracentrifugation, small-angle X-ray scattering and electron microscopy. *Journal of Molecular Biology*. 2007;**365**:187-195. DOI: 10.1016/j.jmb.2006.09.070
- [44] Yanagihara I, Nakahira K, Yamane T, Kaieda S, Mayanagi K, Hamada D, et al. Structure and functional characterization of *Vibrio parahaemolyticus* thermostable direct hemolysin. *The Journal of Biological Chemistry*. 2010;**285**:16267-16274. DOI: 10.1074/jbc.M109.074526
- [45] Honda T, Ni Y, Miwatani T. Purification and characterization of a hemolysin produced by a clinical isolate of Kanagawa phenomenon-negative *Vibrio parahaemolyticus* and related to the thermostable direct hemolysin. *Infection and Immunity*. 1988;**56**:961-965
- [46] Nishibuchi M, Khaeomanee-iam V, Honda T, Kaper JB, Miwatani T. Comparative analysis of the hemolysin genes of *Vibrio cholerae* non-O1, *V. mimicus*, and *V. hollisae* that are similar to the *tdh* gene of *V. parahaemolyticus*. *FEMS Microbiology Letters*. 1990;**67**:251-256. DOI: 10.1016/0378-1097(90)90004-a
- [47] Yoh M, Honda T, Miwatani T. Purification and partial characterization of a non-O1 *Vibrio cholerae* hemolysin that cross-reacts with thermostable direct hemolysin of *Vibrio parahaemolyticus*. *Infection and Immunity*. 1986;**52**:319-322
- [48] Yoshida H, Honda T, Miwatani T. Purification and characterization of a hemolysin of *Vibrio mimicus* that relates to the thermostable direct hemolysin of *Vibrio parahaemolyticus*. *FEMS Microbiology Letters*; **84**:249-254. DOI: 10.1016/0378-1097(91)90364-G

- [49] Yoh M, Honda T, Miwatani T. Purification and partial characterization of a *Vibrio hollisae* hemolysin that relates to the thermostable direct hemolysin of *Vibrio parahaemolyticus*. Canadian Journal of Microbiology. 1986;**32**: 632-636. DOI: 10.1139/m86-118
- [50] Honda T, Ni Y, Miwatani T, Adachi T, Kim J. The thermostable direct haemolysin of *Vibrio parahaemolyticus* is a pore-forming toxin. Canadian Journal of Microbiology. 1992;**38**:1175-1180. DOI: 10.1139/m92-192
- [51] Zen-Yoji H, Hitokoto H, Morozumi S, Le Clair RA. Purification and characterization of a hemolysin produced by *Vibrio parahaemolyticus*. The Journal of Infectious Diseases. 1971;**123**:665-667. DOI: 10.1093/infdis/123.6.665
- [52] Baba K, Yamasaki S, Nishibuchi M, Takeda Y. Examination by site-directed mutagenesis of the amino acid residues of the thermostable direct hemolysin of *Vibrio parahaemolyticus* required for its hemolytic activity. Microbial Pathogenesis. 1992;**12**:279-287. DOI: 10.1016/0882-4010(92)90046-Q
- [53] Takahashi A, Sato Y, Shiomi Y, Cantarelli VV, Iida T, Lee M, et al. Mechanisms of chloride secretion induced by thermostable direct haemolysin of *Vibrio parahaemolyticus* in human colonic tissue and a human intestinal epithelial cell line. Journal of Medical Microbiology. 2000;**49**:801-810. DOI: 10.1099/0022-1317-49-9-801
- [54] Park KS, Ono T, Rokuda M, Jang MH, Lida T, Honda T. Cytotoxicity and enterotoxicity of the thermostable direct hemolysin-deletion mutants of *Vibrio parahaemolyticus*. Microbiology and Immunology. 2004;**48**:313-318. DOI: 10.1111/j.1348-0421.2004.tb03512.x
- [55] Matsuda S, Okada R, Tandhavanat S, Hiyoshi H, Gotoh K, Iida T, et al. Export of a *Vibrio parahaemolyticus* toxin by the sec and type III secretion machineries in tandem. Nature Microbiology. 2019;**4**:781-788. DOI: 10.1038/s41564-019-0368-y
- [56] Kishishita M, Matsuoka N, Kumagai K, Yamasaki S, Takeda Y, Nishibuchi M. Sequence variation in the thermostable direct hemolysin-related hemolysin (*trh*) gene of *Vibrio parahaemolyticus*. Applied and Environmental Microbiology. 1992;**58**:2449-2457
- [57] Baba K, Shirai H, Terai A, Takeda Y, Nishibuchi M. Analysis of the *tdh* gene cloned from a *tdh* gene- and *trh* gene-positive strain of *Vibrio parahaemolyticus*. Microbiology and Immunology. 1991;**35**:253-258. DOI: 10.1111/j.1348-0421.1991.tb01554.x
- [58] Nishibuchi M, Kaper JB. Duplication and variation of the thermostable direct haemolysin (*tdh*) gene in *Vibrio parahaemolyticus*. Molecular Microbiology. 1990;**4**:87-99. DOI: 10.1111/j.1365-2958.1990.tb02017.x
- [59] Takahashi A, Kenjyo N, Imura K, Myonsun Y, Honda T. Cl⁻ secretion in colonic epithelial cells induced by the *Vibrio parahaemolyticus* hemolytic toxin related to thermostable direct hemolysin. Infection and Immunity. 2000;**68**:5435-5438. DOI: 10.1128/iai.68.9.5435-5438.2000
- [60] Nishibuchi M, Ishibashi M, Takeda Y, Kaper JB. Detection of the thermostable direct hemolysin gene and related DNA sequences in *Vibrio parahaemolyticus* and other *Vibrio* species by the DNA colony hybridization test. Infection and immunity. 1985;**49**:481-486
- [61] Honda T, Nishibuchi M, Miwatani T, Kaper JB. Demonstration of a plasmid-borne gene encoding a thermostable direct hemolysin in *Vibrio cholerae* non-O1 strains. Applied and Environmental Microbiology. 1986;**52**:1218-1220

- [62] Cai SH, Wu ZH, Jian JC, Lu YS. Cloning and expression of gene encoding the thermostable direct hemolysin from *Vibrio alginolyticus* strain HY9901, the causative agent of vibriosis of crimson snapper (*Lutjanus erythropterus*). Journal of Applied Microbiology. 2007;**103**:289-296. DOI: 10.1111/j.1365-2672.2006.03250.x
- [63] Ichinose Y, Yamamoto K, Nakasone N, Tanabe MJ, Takeda T, Miwatani T, et al. Enterotoxigenicity of El tor-like hemolysin of non-O1 *Vibrio cholerae*. Infection and Immunity. 1987;**55**:1090-1093
- [64] Ghosh A, Saha DR, Hoque KM, Asakuna M, Yamasaki S, Koley H, et al. Enterotoxigenicity of mature 45-kilodalton and processed 35-kilodalton forms of hemagglutinin protease purified from a cholera toxin gene-negative *Vibrio cholerae* non-O1, non-O139 strain. Infection and Immunity. 2006;**74**:2937-2946. DOI: 10.1128/IAI.74.5.2937-2946.2006
- [65] Shin OS, Tam VC, Suzuki M, Ritchie JM, Bronson RT, Waldor MK, et al. Type III secretion is essential for the rapidly fatal diarrheal disease caused by non-O1, non-O139 *Vibrio cholerae*. MBio. 2011;**2**:e00106-e00111. DOI: 10.1128/mBio.00106-11
- [66] Yamamoto K, Al-Omani M, Honda T, Takeda Y, Miwatani T. Non-O1 *Vibrio cholerae* hemolysin: Purification, partial characterization, and immunological relatedness to El tor hemolysin. Infection and Immunity. 1984;**45**:192-196
- [67] Yamamoto K, Ichinose Y, Nakasone N, Tanabe M, Nagahama M, Sakurai J, et al. Identity of hemolysins produced by *Vibrio cholerae* non-O1 and *V. cholerae* O1, biotype El tor. Infection and immunity. 1986;**51**:927-931
- [68] Zitzer A, Wassenaar TM, Walev I, Bhakdi S. Potent membrane-permeabilizing and cytotoxic action of *Vibrio cholerae* cytolysin on human intestinal cells. Infection and Immunity. 1997;**65**:1293-1298
- [69] Alm RA, Stroehrer UH, Manning PA. Extracellular proteins of *Vibrio cholerae*: Nucleotide sequence of the structural gene (*hlyA*) for the haemolysin of the haemolytic El tor strain O17 and characterization of the *hlyA* mutation in the non-haemolytic classical strain 569B. Molecular Microbiology. 1988;**2**:481-488
- [70] Rader AE, Murphy JR. Nucleotide sequences and comparison of the hemolysin determinants of *Vibrio cholerae* El tor RV79(Hly+) and RV79(Hly-) and classical 569B(Hly-). Infection and Immunity. 1988;**56**:1414-1419
- [71] Yamamoto K, Ichinose Y, Shinagawa H, Makino K, Nakata A, Iwanaga M, et al. Two-step processing for activation of the cytolysin/hemolysin of *Vibrio cholerae* O1 biotype El tor: Nucleotide sequence of the structural gene (*hlyA*) and characterization of the processed products. Infection and Immunity. 1990;**58**:4106-4116
- [72] Nagamune K, Yamamoto K, Naka A, Matsuyama J, Miwatani T, Honda T. In vitro proteolytic processing and activation of the recombinant precursor of El tor cytolysin/hemolysin (pro-HlyA) of *Vibrio cholerae* by soluble hemagglutinin/protease of *V. cholerae*, trypsin, and other proteases. Infection and Immunity. 1996;**64**:4655-4658
- [73] Valeva A, Walev I, Weis S, Boukhallouk F, Wassenaar TM, Endres K, et al. Acellular metalloproteinase activates *Vibrio cholerae* pro-cytolysin. The Journal of Biological Chemistry. 2004;**279**:25143-25148. DOI: 10.1074/jbc.M313913200
- [74] Nagamune K, Yamamoto K, Honda T. Intramolecular chaperone

- activity of the pro-region of *Vibrio cholerae* El tor cytolysin. The Journal of Biological Chemistry. 1997;272:1338-1343. DOI: 10.1074/jbc.272.2.1338
- [75] Song L, Hobaugh MR, Shustak C, Cheley S, Bayley H, Gouaux JE. Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore. Science. 1996;274:1859-1866. DOI: 10.1126/science.274.5294.1859
- [76] Parker MW, Buckley JT, Postma JP, Tucker AD, Leonard K, Pattus F, et al. Structure of the *Aeromonas* toxin proaerolysin in its water-soluble and membrane-channel states. Nature. 1994;367:292-295. DOI: 10.1038/367292a0
- [77] Los FC, Randis TM, Aroian RV, Ratner AJ. Role of pore-forming toxins in bacterial infectious diseases. Microbiology and Molecular Biology Reviews. 2013;77:173-207. DOI: 10.1128/MMBR.00052-12
- [78] Olson R, Gouaux E. Crystal structure of the *Vibrio cholerae* cytolysin (VCC) pro-toxin and its assembly into a heptameric transmembrane pore. Journal of Molecular Biology. 2005;350:997-1016. DOI: 10.1016/j.jmb.2005.05.045
- [79] He Y, Olson R. Three-dimensional structure of the detergent-solubilized *Vibrio cholerae* cytolysin (VCC) heptamer by electron cryomicroscopy. Journal of Structural Biology. 2010;169:6-13. DOI: 10.1016/j.jsb.2009.07.015
- [80] De S, Olson R. Crystal structure of the *Vibrio cholerae* cytolysin heptamer reveals common features among disparate pore-forming toxins. Proceedings of the National Academy of Sciences of the United States of America. 2011;108:7385-7390. DOI: 10.1073/pnas.1017442108
- [81] Löhner S, Walev I, Boukhallouk F, Palmer M, Bhakdi S, Valeva A. Pore formation by *Vibrio cholerae* cytolysin follows the same archetypical mode as beta-barreltoxins from gram-positive organisms. The FASEB Journal. 2009;23:2521-2528. DOI: 10.1096/fj.08-127688
- [82] Krasilnikov OV, Muratkhodjaev JN, Zitzer AO. The mode of action of *Vibrio cholerae* cytolysin. The influences on both erythrocytes and planar lipid bilayers. Biochimica et Biophysica Acta. 1992;1111:7-16. DOI: 10.1016/0005-2736(92)90268-Q
- [83] Figueroa-Arredondo P¹, Heuser JE, Akopyants NS, Morisaki JH, Giono-Cerezo S, Enríquez-Rincón F, Berg DE. Cell vacuolation caused by *Vibrio cholerae* hemolysin. Infection and Immunity 2001;69:1613-1624. DOI:10.1128/IAI.69.3.1613-1624.2001
- [84] Saka HA, Bidinost C, Sola C, Carranza P, Collino C, Ortiz S, et al. *Vibrio cholerae* cytolysin is essential for high enterotoxicity and apoptosis induction produced by a cholera toxin gene-negative *V. cholerae* non-O1, non-O139 strain. Microbial Pathogenesis. 2008;44:118-128
- [85] Mukherjee G, Biswas A, Banerjee KK, Biswas T. *Vibrio cholerae* hemolysin is apoptogenic to peritoneal B-1a cells but its oligomer shepherd the cells for IgA response. Molecular Immunology. 2008;45:266-270. DOI: 10.1016/j.molimm.2007.04.024
- [86] Tweten RK. Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. Infection and Immunity. 2005;73:6199-6209. DOI: 10.1128/IAI.73.10.6199-6209.2005
- [87] Fivaz M, Vilbois F, Thurnheer S, Pasquali C, Abrami L, Bickel PE, Parton RG, van der Goot FG. Differential sorting and fate of endocytosed GPI-anchored proteins. The EMBO Journal 2002;21:3989-4000. DOI: 10.1093/emboj/cdf398

- [88] Giddings KS, Zhao J, Sims PJ, Tweten RK. Human CD59 is a receptor for the cholesterol-dependent cytolysin intermedilysin. *Nature Structural and Molecular Biology*. 2004;**1**:1173-1178. DOI: 10.1038/nsmb862
- [89] Zhang D, Takahashi J, Seno T, Tani Y, Honda T. Analysis of receptor for *Vibrio cholerae* El tor hemolysin with a monoclonal antibody that recognizes glycophorin B of human erythrocyte membrane. *Infection and Immunity*. 1999;**67**:5332-5337
- [90] Saha N, Banerjee KK. Carbohydrate-mediated regulation of interaction of *Vibrio cholerae* hemolysin with erythrocyte and phospholipids vesicle. *The Journal of Biological Chemistry*. 1997;**272**:162-167. DOI: 10.1074/jbc.272.1.162
- [91] Zitzer A, Zitzer O, Bhakdi S, Palmer M. Oligomerization of *Vibrio cholerae* cytolysin yields a pentameric pore and has a dual specificity for cholesterol and sphingolipids in the target membrane. *The Journal of Biological Chemistry*. 1999;**274**: 1375-1380. DOI: 10.1074/jbc.274.3.137
- [92] Levan S, De S, Olson R. *Vibrio cholerae* cytolysin recognizes the heptasaccharide core of complex N-glycans with nanomolar affinity. *Journal of Molecular Biology*. 2013;**425**:944-957. DOI: 10.1016/j.jmb.2012.12.016
- [93] Dutta S, Mazumdar B, Banerjee KK, Ghosh AN. Three-dimensional structure of different functional forms of the *Vibrio cholerae* hemolysin oligomer: A cryo-electron microscopic study. *Journal of Bacteriology*. 2010;**192**:169-178. DOI: 10.1128/JB.00930-09
- [94] Mazumdar B, Ganguly S, Ghosh AN, Banerjee KK. The role of C-terminus carbohydrate-binding domain of *Vibrio cholerae* haemolysin/ cytolysin in the conversion of the pre-pore β -barrel oligomer to a functional diffusion channel. *The Indian Journal of Medical Research*. 2011;**133**:131-137
- [95] Ganguly S, Mukherjee A, Mazumdar B, Ghosh AN, Banerjee KK. The β -prism lectin domain of *Vibrio cholerae* hemolysin promotes self-assembly of the β -pore-forming toxin by a carbohydrate-independent mechanism. *The Journal of Biological Chemistry*. 2014;**289**:4001-4008. DOI: 10.1074/jbc.M113.522284
- [96] Mukherjee A, Ganguly S, Chatterjee NS, Banerjee KK. *Vibrio cholerae* hemolysin: The β -trefoil domain is required for folding to the native conformation. *Biochemistry and Biophysics Reports*. 2016;**8**:242-248. DOI: 10.1016/j.bbrep.2016.09.009
- [97] Rai AK, Chattopadhyay K. Revisiting the membrane interaction mechanism of a membrane-damaging β -barrel pore-forming toxin *Vibrio cholerae* cytolysin. *Molecular Microbiology*. 2015;**97**:1051-1062. DOI: 10.1111/mmi.13084
- [98] Rai AK, Chattopadhyay K. Trapping of *Vibrio cholerae* cytolysin in the membrane-bound monomeric state blocks membrane insertion and functional pore formation by the toxin. *The Journal of Biological Chemistry*. 2014;**289**:16978-16987. DOI: 10.1074/jbc.M114.567099
- [99] Paul K, Chattopadhyay K. Pre-pore oligomer formation by *Vibrio cholerae*: Insights from a truncated variant lacking the pore-forming pre-stem loop. *Biochemical and Biophysical Research Communications*. 2014;**443**:189-193. DOI: 10.1016/j.bbrc.2013.11.078
- [100] Miyoshi S, Sasahara K, Akamatsu S, Rahman MM, Katsu T, Tomochika K, et al. Purification and characterization of a hemolysin produced by *Vibrio mimicus*. *Infection and Immunity*. 1997;**65**:1830-1835

- [101] Yamanaka H, Satoh T, Katsu T, Shinoda S. Mechanism of haemolysis by *Vibrio vulnificus* haemolysin. *Journal of General Microbiology*. 1987;**133**:2859-2864. DOI: 10.1099/00221287-133-10-2859
- [102] Kothary MH, Lowman H, McCardell BA, Tall BD. Purification and characterization of enterotoxigenic El tor-like hemolysin produced by *Vibrio fluvialis*. *Infection and Immunity*. 2003;**71**:3213-3220. DOI: 10.1128/IAI.71.6.3213-3220.2003
- [103] Davis BR, Fanning GR, Madden JM, Steigerwalt AG, Bradford HB Jr, Smith HL, et al. Characterization of biochemically atypical *Vibrio cholerae* strains and designation of a new pathogenic species, *Vibrio mimicus*. *Journal of Clinical Microbiology*. 1981;**14**:631-639
- [104] Hoge CW, Watsky D, Pealer RN, Libonati JP, Israel E, Morris JG Jr. Epidemiology and spectrum of *Vibrio* infections in a Chesapeake Bay community. *The Journal of Infectious Diseases*. 1989;**160**:985-993. DOI: 10.1093/infdis/160.6.985
- [105] Ramamurthy T, Albert MJ, Huq A, Colwell RR, Takeda Y, Takeda T, et al. *Vibrio mimicus* with multiple toxin types isolated from human and environmental sources. *Journal of Medical Microbiology*. 1994;**40**:194-196. DOI: 10.1099/00222615-40-3-194
- [106] Shinoda S, Miyoshi S. Enteropathogenic factors produced by vibrios other than cholera toxin. *Journal of Natural Toxins*. 2000;**9**:231-249
- [107] Spira WM, Fedorka-Cray PJ. Purification of enterotoxin from *Vibrio mimicus* that appear to be identical to cholera toxin. *Infection and Immunity*. 1984;**45**:679-684
- [108] Chowdhury MAR, Aziz KMS, Kay BA, Rahim Z. Toxin production by *Vibrio mimicus* strains isolated from human and environmental sources in Bangladesh. *Journal of Clinical Microbiology*. 1987;**25**:2200-2203
- [109] Shi L, Miyoshi S, Bi K, Nakamura M, Hiura M, Tomochika K, et al. Presence of hemolysin genes (*vmh*, *tdh* and *hlx*) in isolates of *Vibrio mimicus* determined by polymerase chain reaction. *The Journal of Health Science*. 2000;**46**:63-65
- [110] Shinoda S, Nakagawa T, Shi L, Bi K, Kanoh Y, Tomochika K, et al. Distribution of virulence-associated genes in *Vibrio mimicus* isolates from clinical and environmental origins. *Microbiology and Immunology*. 2004;**48**:547-551. DOI: 10.1111/j.1348-0421.2004.tb03551.x
- [111] Li Y, Okamoto K, Takahashi E, Miyoshi S, Shinoda S, Tsuji T, et al. A hemolysin of *Vibrio mimicus* (VMH) stimulates cells to produce ATP and cyclic AMP which appear to be secretory mediators. *Microbiology and Immunology*. 2005;**49**:73-78. DOI: 10.1111/j.1348-0421.2005.tb03631.x
- [112] Takahashi A, Miyoshi S, Takata N, Nakano M, Hamamoto A, Mawatari K, et al. Haemolysin produced by *Vibrio mimicus* activates two Cl⁻ secretory pathways in cultured intestinal-like Caco-2 cells. *Cellular Microbiology*. 2007;**9**:583-595. DOI: 10.1111/j.1462-5822.2006.00809.x
- [113] Sultan Z, Mizuno T, Sakurai A, Takata N, Okamoto K, Miyoshi S. Growth phase dependant activation of the precursor of *Vibrio mimicus* hemolysin (pro-VMH). *The Journal of Health Science*. 2007;**53**:430-434. DOI: 10.1248/jhs.53.430
- [114] Rahman MM, Miyoshi S, Tomochika K, Wakae H, Shinoda S.

Analysis of the structural gene encoding a hemolysin in *Vibrio mimicus*. Microbiology and Immunology. 1997;**41**:169-173. DOI: 10.1111/j.1348-0421.1997.tb01183.x

[115] Mizuno T, Nanko A, Maehara Y, Shinoda S, Miyoshi S. A novel extracellular protease of *Vibrio mimicus* that mediates maturation of an endogenous hemolysin. Microbiology and Immunology. 2014;**58**:503-512. DOI: 10.1111/1348-0421.12177

[116] Mizuno T, Sultan SZ, Kaneko Y, Yoshimura T, Maehara Y, Nakao H, et al. Modulation of *Vibrio mimicus* hemolysin through limited proteolysis by an endogenous metalloprotease. The FEBS Journal. 2009;**276**:825-834. DOI: 10.1111/j.1742-4658.2008.06827.x

[117] Chowdhury G, Pazhani GP, Dutta D, Guin S, Dutta S, Ghosh S, et al. *Vibrio fluvialis* in patients with diarrhea, Kolkata, India. Emerging Infectious Diseases. 2012;**18**:1868-1871. DOI: 10.3201/eid1811.120520

[118] Liang P, Cui XY, Du XL, Kan B, Liang WL. The virulence phenotypes and molecular epidemiological characteristics of *Vibrio fluvialis* in China. Gut Pathogen. 2013;**5**:6. DOI: 10.1186/1757-4749-5-6

[119] Ramamurthy T, Chowdhury G, Pazhani GP, Shinoda S. *Vibrio fluvialis*: An emerging human pathogen. Frontiers in Microbiology. 2014;**5**:91. DOI: 10.3389/fmicb.2014.00091

[120] Roland FP. Leg gangrene and endotoxin shock due to *Vibrio parahaemolyticus*: An infection acquired in New England coastal waters. The New England Journal of Medicine. 1970;**282**:1306. DOI: 10.1056/NEJM197006042822306

[121] Klontz KC, Lieb S, Schreiber M, Janowski HT, Baldy LM, Gunn RA.

Syndromes of *Vibrio vulnificus* infections: Clinical and epidemiological features in Florida cases, 1981-1987. Annals of Internal Medicine. 1988;**109**:318-323. DOI: 10.7326/0003-4819-109-4-318

[122] Oliver JD. The viable but non-culturable state in the human pathogen *Vibrio vulnificus*. FEMS Microbiology Letters. 1995;**133**:203-208. DOI: 10.1111/j.1574-6968.1995.tb07885.x

[123] Miyoshi S, Oh EG, Hirata K, Shinoda S. Exocellular toxic factors produced by *Vibrio vulnificus*. Journal of Toxicology - Toxin Reviews. 1993;**12**:253-288. DOI: 10.3109/15569549309014409

[124] Miyoshi S, Shinoda S. Bacterial metalloprotease as the toxic factor in infection. Journal of Toxicology - Toxin Reviews. 1997;**16**:177-194. DOI: 10.3109/15569549709016455

[125] Kreger A, Lockwood D. Detection of extracellular toxin(s) produced by *Vibrio vulnificus*. Infection and Immunity. 1981;**33**:583-590

[126] Yamanaka H, Sugiyama K, Furuta H, Miyoshi S, Shinoda S. Cytolytic action of *Vibrio vulnificus* haemolysin on mast cells from rat peritoneal cavity. Journal of Medical Microbiology. 1990;**32**:39-43. DOI: 10.1099/00222615-32-1-39

[127] Kim JS. Cytotoxicity of *Vibrio vulnificus* cytolysin on pulmonary endothelial cells. Experimental and Molecular Medicine. 1997;**29**:117-121. DOI: 10.1038/emmm.1997.17

[128] Kwon KB, Yang JY, Ryu DG, Rho HW, Kim JS, Park JW, et al. *Vibrio vulnificus* cytolysin induces superoxide anion-initiated apoptotic signaling pathway in human ECV304 cells. The Journal of Biological Chemistry.

- 2001;**276**:47518-47523. DOI: 10.1074/jbc.M108645200
- [129] Kashimoto T, Ueno S, Ehara H, Fukudome S, Komai M, Susa N. Oligomerization is essential for apoptotic activity of *Vibrio vulnificus* hemolysin. The Journal of Veterinary Medical Science. 2009;**71**:1403-1406. DOI: 10.1292/jvms.001403
- [130] Kaus K, Lary JW, Cole JL, Olson R. Glycan specificity of the *Vibrio vulnificus* hemolysin lectin outlines evolutionary history of membrane targeting by a toxin family. Journal of Molecular Biology. 2014;**426**:2800-2812. DOI: 10.1016/j.jmb.2014.05.021
- [131] Senoh M, Okita Y, Shinoda S, Miyoshi S. The crucial amino acid residue related to inactivation of *Vibrio vulnificus* hemolysin. Microbial Pathogenesis. 2008;**44**:78-83. DOI: 10.1016/j.micpath.2007.07.002
- [132] Sugiyama H, Kashimoto T, Ueno S, Susa N. Inhibition of binding of *Vibrio vulnificus* hemolysin (VVH) by M β CD. The Journal of Veterinary Medical Science. 2013;**75**:649-452. DOI: 10.1292/jvms.12-0387
- [133] Shinoda S, Miyoshi S, Yamanaka H, Miyoshi-Nakahara N. Some properties of *Vibrio vulnificus* hemolysin. Microbiology and Immunology. 1985;**29**:583-590
- [134] Kim HR, Rho HW, Jeong MH, Park JW, Kim JS, Park BH, et al. Hemolytic mechanism of cytolysin produced from *V. vulnificus*. Life Sciences. 1993;**53**:571-577. DOI: 10.1016/0024-3205(93)90714-e
- [135] Kim BS, Kim JS. Cholesterol induce oligomerization of *Vibrio vulnificus* cytolysin specifically. Experimental and Molecular Medicine. 2002;**34**:239-242. DOI: 10.1038/emm.2002.33
- [136] Kashimoto T, Ueno S, Koga T, Fukudome S, Ehara H, Komai M, et al. The aromatic ring of phenylalanine 334 is essential for oligomerization of *Vibrio vulnificus* hemolysin. Journal of Bacteriology. 2010;**192**:568-574. DOI: 10.1128/JB.01049-09
- [137] Miyoshi S, Abe Y, Senoh M, Mizuno T, Maehara Y, Nakao H. Inactivation of *Vibrio vulnificus* hemolysin through mutation of the N- or C-terminus of the lectin-like domain. Toxicon. 2011;**57**:904-908. DOI: 10.1016/j.toxicon.2011.03.013
- [138] Kashimoto T, Akita T, Kado T, Yamazaki K, Ueno S. Both polarity and aromatic ring in the side chain of tryptophan 246 are involved in binding activity of *Vibrio vulnificus* hemolysin to target cells. Microbial Pathogenesis. 2017;**109**:71-77. DOI: 10.1016/j.micpath.2017.05.029
- [139] Kothary MH, Delston RB, Curtis SK, McCardell BA, Tall BD. Purification and characterization of a vulnificolysin-like cytolysin produced by *Vibrio tubiashii*. Applied and Environmental Microbiology. 2001;**67**:3707-3711. DOI: 10.1128/AEM.67.8.3707-3711.2001
- [140] Alvarez JR, Lamba S, Dyer KY, Apuzzio JJ. An unusual case of urinary tract infection in a pregnant woman with *Photobacterium damsela*. Infectious Diseases in Obstetrics and Gynecology. 2006;**80682**:1-3. DOI: 10.1155/IDOG/2006/80682
- [141] Asato J, Kanaya F. Fatal infection of the hand due to *Photobacterium damsela*: A case report. Clinical Infectious Diseases. 2004;**38**:e100-e101. DOI: 10.1086/383468
- [142] Kim HR, Kim JW, Lee MK, Kim JG. Septicemia progressing to fatal hepatic dysfunction in a cirrhotic patient after oral ingestion of *Photobacterium damsela*: A case

report. Infection. 2009;37:555-556. DOI: 10.1007/s15010-009-9049-8

[143] Yamane K, Asato J, Kawade N, Takahashi H, Kimura B, Arakawa Y. Two cases of fatal necrotizing fasciitis caused by *Photobacterium damsela* in Japan. Journal of Clinical Microbiology. 2004;42:1370-1372. DOI: 10.1128/jcm.42.3.1370-1372.2004

[144] Kreger AS, Bernheimer AW, Etkin LA, Daniel LW. Phospholipase D activity of *Vibrio damsela* cytolysin and its interaction with sheep erythrocytes. Infection and Immunity. 1987;55:3209-3212

[145] Rivas AJ, Balado M, Lemos ML, Osorio CR. The *Photobacterium damsela* subsp. *damsela* hemolysins *damselysin* and *HlyA* are encoded within a new virulence plasmid. Infection and Immunity. 2011;79:4617-4627. DOI: 10.1128/IAI.05436-11